1 |
Han DH, Kwon OK, Byun BJ, Choi BY, Choi CW, Choi JU, et al. : A co-operative study : clinical characteristics of 334 Korean patients with moyamoya disease treated at neurosurgical institutes (1976-1994). The Korean Society for Cerebrovascular Disease. Acta Neurochir (Wien) 142 : 1263-1273; discussion 1273-1274, 2000
DOI
|
2 |
Ikeda E, Achen MG, Breier G, Risau W : Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270 : 19761-19766, 1995
DOI
|
3 |
Li H, Zhang ZS, Liu W, Yang WZ, Dong ZN, Ma MJ, et al. : Association of a functional polymorphism in the MMP-3 gene with Moyamoya Disease in the Chinese Han population. Cerebrovasc Dis 30 : 618-625, 2010
DOI
|
4 |
Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T : Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet 64 : 533-537, 1999
DOI
|
5 |
Liu W, Hashikata H, Inoue K, Matsuura N, Mineharu Y, Kobayashi H, et al. : A rare Asian founder polymorphism of Raptor may explain the high prevalence of moyamoya disease among East Asians and its low prevalence among Caucasians. Environ Health Prev Med 15 : 94-104, 2010
DOI
|
6 |
Park YS, Jeon YJ, Kim HS, Han IB, Choi JU, Kim DS, et al. : The roles of methylenetetrahydrofolate reductase 677C>T and 1298A>C polymorphisms in moyamoya disease patients. Childs Nerv Syst 30 : 1687-1695, 2014
DOI
|
7 |
Skardoutsou A, Voudris KA, Mastroyianni S, Vagiakou E, Magoufis G, Koukoutsakis P : Moya moya syndrome in a child with pyruvate kinase deficiency and combined prothrombotic factors. J Child Neurol 22 : 474-478, 2007
DOI
|
8 |
Han DH, Nam DH, Oh CW : Moyamoya disease in adults : characteristics of clinical presentation and outcome after encephalo-duro-arterio-synangiosis. Clin Neurol Neurosurg 99 Suppl 2 : S151-S155, 1997
DOI
|
9 |
Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, et al. : Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273 : 30336-30343, 1998
DOI
|
10 |
Guo DC, Papke CL, Tran-Fadulu V, Regalado ES, Avidan N, Johnson RJ, et al. : Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet 84 : 617-627, 2009
DOI
|
11 |
Han H, Pyo CW, Yoo DS, Huh PW, Cho KS, Kim DS : Associations of Moyamoya patients with HLA class I and class II alleles in the Korean population. J Korean Med Sci 18 : 876-880, 2003
DOI
|
12 |
Hojo M, Hoshimaru M, Miyamoto S, Taki W, Nagata I, Asahi M, et al. : Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J Neurosurg 89 : 623-629, 1998
DOI
|
13 |
Hong SH, Wang KC, Kim SK, Cho BK, Park MH : Association of HLA-DR and -DQ genes with familial Moyamoya disease in Koreans. J Korean Neurosurg Soc 46 : 558-563, 2009
DOI
|
14 |
Hoshimaru M, Takahashi JA, Kikuchi H, Nagata I, Hatanaka M : Possible roles of basic fibroblast growth factor in the pathogenesis of moyamoya disease : an immunohistochemical study. J Neurosurg 75 : 267-270, 1991
DOI
|
15 |
Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M : Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol 15 : 179-182, 2000
DOI
|
16 |
Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. : A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet 56 : 34-40, 2011
DOI
|
17 |
Inoue TK, Ikezaki K, Sasazuki T, Ono T, Kamikawaji N, Matsushima T, et al. : DNA typing of HLA in the patients with moyamoya disease. Jpn J Hum Genet 42 : 507-515, 1997
DOI
|
18 |
Issa R, Krupinski J, Bujny T, Kumar S, Kaluza J, Kumar P : Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. Lab Invest 79 : 417-425, 1999
|
19 |
Jin KL, Mao XO, Nagayama T, Goldsmith PC, Greenberg DA : Induction of vascular endothelial growth factor and hypoxia-inducible factor-1alpha by global ischemia in rat brain. Neuroscience 99 : 577-585, 2000
DOI
|
20 |
Kastrup A, Schulz JB, Mader I, Dichgans J, Küker W : Diffusion-weighted MRI in patients with symptomatic internal carotid artery disease. J Neurol 249 : 1168-1174, 2002
DOI
|
21 |
Kim SH, Hwang H, Chae JH, Kim KJ, Hwang YS, Lim BC : Ischemic stroke in a 7-month-old infant with antiphospholipid antibody and homozygous C677T methylenetetrahydrofolate reductase (MTHFR) polymorphism. J Child Neurol 25 : 1047-1050, 2010
DOI
|
22 |
Kim SK, Yoo JI, Cho BK, Hong SJ, Kim YK, Moon JA, et al. : Elevation of CRABP-I in the cerebrospinal fluid of patients with Moyamoya disease. Stroke 34 : 2835-2841, 2003
DOI
|
23 |
Kitahara T, Okumura K, Semba A, Yamaura A, Makino H : Genetic and immunologic analysis on moya-moya. J Neurol Neurosurg Psychiatry 45 : 1048-1052, 1982
DOI
|
24 |
Kraemer M, Horn PA, Roder C, Khan N, Diehl RR, Berlit P, et al. : Analysis of human leucocyte antigen genes in Caucasian patients with idiopathic moyamoya angiopathy. Acta Neurochir (Wien) 154 : 445-454, 2012
DOI
|
25 |
Lee SR, Lo EH : Induction of caspase-mediated cell death by matrix metalloproteinases in cerebral endothelial cells after hypoxia-reoxygenation. J Cereb Blood Flow Metab 24 : 720-727, 2004
DOI
|
26 |
Kuroda S, Hashimoto N, Yoshimoto T, Iwasaki Y; Research Committee on Moyamoya Disease in Japan : Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease : results of multicenter survey in Japan. Stroke 38 : 1430-1435, 2007
DOI
|
27 |
Kuroda S, Houkin K : Moyamoya disease : current concepts and future perspectives. Lancet Neurol 7 : 1056-1066, 2008
DOI
|
28 |
Lee CZ, Xu B, Hashimoto T, McCulloch CE, Yang GY, Young WL : Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke 35 : 1715-1719, 2004
DOI
|
29 |
Liu C, Roder C, Schulte C, Kasuya H, Akagawa H, Nishizawa T, et al. : Analysis of TGFB1 in European and Japanese Moyamoya disease patients. Eur J Med Genet 55 : 531-534, 2012
DOI
|
30 |
Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, et al. : Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 6 : e22542, 2011
DOI
|
31 |
Liu W, Senevirathna ST, Hitomi T, Kobayashi H, Roder C, Herzig R, et al. : Genomewide association study identifies no major founder variant in Caucasian moyamoya disease. J Genet 92 : 605-609, 2013
DOI
|
32 |
Lo EH, Dalkara T, Moskowitz MA : Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4 : 399-415, 2003
|
33 |
Malek AM, Connors S, Robertson RL, Folkman J, Scott RM : Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and central nervous system disorders. Pediatr Neurosurg 27 : 182-189, 1997
DOI
|
34 |
Miyatake S, Touho H, Miyake N, Ohba C, Doi H, Saitsu H, et al. : Sibling cases of moyamoya disease having homozygous and heterozygous c.14576G>A variant in RNF213 showed varying clinical course and severity. J Hum Genet 57 : 804-806, 2012
DOI
|
35 |
McKasson MJ, Golomb MR : Two children with both arm ischemia and arterial ischemic stroke during the perinatal period. J Child Neurol 26 : 1548-1554, 2011
DOI
|
36 |
Mineharu Y, Liu W, Inoue K, Matsuura N, Inoue S, Takenaka K, et al. : Autosomal dominant moyamoya disease maps to chromosome 17q25.3. Neurology 70 (24 Pt 2) : 2357-2363, 2008
DOI
|
37 |
Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I, et al. : Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology 78 : 803-810, 2012
DOI
|
38 |
Miyawaki S, Imai H, Takayanagi S, Mukasa A, Nakatomi H, Saito N : Identification of a genetic variant common to moyamoya disease and intracranial major artery stenosis/occlusion. Stroke 43 : 3371-3374, 2012
DOI
|
39 |
Moncada S, Higgs A : The L-arginine-nitric oxide pathway. N Engl J Med 329 : 2002-2012, 1993
DOI
|
40 |
Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP : Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375 : 577-581, 1995
DOI
|
41 |
Nanba R, Kuroda S, Tada M, Ishikawa T, Houkin K, Iwasaki Y : Clinical features of familial moyamoya disease. Childs Nerv Syst 22 : 258-262, 2006
DOI
|
42 |
Nanba R, Tada M, Kuroda S, Houkin K, Iwasaki Y : Sequence analysis and bioinformatics analysis of chromosome 17q25 in familial moyamoya disease. Childs Nerv Syst 21 : 62-68, 2005
DOI
|
43 |
Roder C, Peters V, Kasuya H, Nishizawa T, Wakita S, Berg D, et al. : Analysis of ACTA2 in European Moyamoya disease patients. Eur J Paediatr Neurol 15 : 117-122, 2011
DOI
|
44 |
Park YS, Jeon YJ, Kim HS, Chae KY, Oh SH, Han IB, et al. : The role of VEGF and KDR polymorphisms in moyamoya disease and collateral revascularization. PLoS One 7 : e47158, 2012
DOI
|
45 |
Park YS, Jeon YJ, Kim HS, Han IB, Oh SH, Kim DS, et al. : The GC + CC genotype at position -418 in TIMP-2 promoter and the -1575GA/-1306CC genotype in MMP-2 is genetic predisposing factors for prevalence of moyamoya disease. BMC Neurol 14 : 180, 2014
DOI
|
46 |
Park YS, Min KT, Kim TG, Lee YH, Cheong HJ, Yeom IS, et al. : Age-specific eNOS polymorphisms in moyamoya disease. Childs Nerv Syst 27 : 1919-1926, 2011
DOI
|
47 |
Roder C, Peters V, Kasuya H, Nishizawa T, Takehara Y, Berg D, et al. : Common genetic polymorphisms in moyamoya and atherosclerotic disease in Europeans. Childs Nerv Syst 27 : 245-252, 2011
DOI
|
48 |
Roder C, Peters V, Kasuya H, Nishizawa T, Takehara Y, Berg D, et al. : Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients. Acta Neurochir (Wien) 152 : 2153-2160, 2010
DOI
|
49 |
Ruel M, Khan TA, Voisine P, Bianchi C, Sellke FW : Vasomotor dysfunction after cardiac surgery. Eur J Cardiothorac Surg 26 : 1002-1014, 2004
DOI
|
50 |
Sakamoto S, Kiura Y, Yamasaki F, Shibukawa M, Ohba S, Shrestha P, et al. : Expression of vascular endothelial growth factor in dura mater of patients with moyamoya disease. Neurosurg Rev 31 : 77-81; discussion 81, 2008
|
51 |
Sakurai K, Horiuchi Y, Ikeda H, Ikezaki K, Yoshimoto T, Fukui M, et al. : A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet 49 : 278-281, 2004
DOI
|
52 |
Starke RM, Komotar RJ, Connolly ES : Optimal surgical treatment for moyamoya disease in adults : direct versus indirect bypass. Neurosurg Focus 26 : E8, 2009
|
53 |
Schork NJ, Fallin D, Lanchbury JS : Single nucleotide polymorphisms and the future of genetic epidemiology. Clin Genet 58 : 250-264, 2000
|
54 |
Scott RM : Arteriovenous malformation and moyamoya disease. Childs Nerv Syst 13 : 357, 1997
DOI
|
55 |
Sonobe S, Fujimura M, Niizuma K, Nishijima Y, Ito A, Shimizu H, et al. : Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213 : a susceptibility gene for moyamoya disease. Brain Res 1552 : 64-71, 2014
DOI
|
56 |
Takekawa Y, Umezawa T, Ueno Y, Sawada T, Kobayashi M : Pathological and immunohistochemical findings of an autopsy case of adult moyamoya disease. Neuropathology 24 : 236-242, 2004
DOI
|
57 |
Thomas KA : Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 271 : 603-606, 1996
DOI
|
58 |
Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R, et al. : Epidemiological features of moyamoya disease in Japan : findings from a nationwide survey. Clin Neurol Neurosurg 99 Suppl 2 : S1-S5, 1997
DOI
|
59 |
Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH : Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269 : 26988-26995, 1994
|
60 |
Wang X, Zhang Z, Liu W, Xiong Y, Sun W, Huang X, et al. : Impacts and interactions of PDGFRB, MMP-3, TIMP-2, and RNF213 polymorphisms on the risk of Moyamoya disease in Han Chinese human subjects. Gene 526 : 437-442, 2013
DOI
|
61 |
Yamashita M, Oka K, Tanaka K : Histopathology of the brain vascular network in moyamoya disease. Stroke 14 : 50-58, 1983
DOI
|
62 |
Weinberg DG, Arnaout OM, Rahme RJ, Aoun SG, Batjer HH, Bendok BR : Moyamoya disease : a review of histopathology, biochemistry, and genetics. Neurosurg Focus 30 : E20, 2011
DOI
|
63 |
Wu Z, Jiang H, Zhang L, Xu X, Zhang X, Kang Z, et al. : Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. PLoS One 7 : e48179, 2012
DOI
|
64 |
Yamamoto M, Aoyagi M, Fukai N, Matsushima Y, Yamamoto K : Differences in cellular responses to mitogens in arterial smooth muscle cells derived from patients with moyamoya disease. Stroke 29 : 1188-1193, 1998
DOI
|
65 |
Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, et al. : Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 31 : 930-935, 2000
DOI
|
66 |
Yoshimoto T, Houkin K, Takahashi A, Abe H : Angiogenic factors in moyamoya disease. Stroke 27 : 2160-2165, 1996
DOI
|
67 |
Aoyagi M, Ogami K, Matsushima Y, Shikata M, Yamamoto M, Yamamoto K : Human leukocyte antigen in patients with moyamoya disease. Stroke 26 : 415-417, 1995
DOI
|
68 |
Achrol AS, Guzman R, Lee M, Steinberg GK : Pathophysiology and genetic factors in moyamoya disease. Neurosurg Focus 26 : E4, 2009
|
69 |
Andreone V, Ciarmiello A, Fusco C, Ambrosanio G, Florio C, Linfante I : Moyamoya disease in Italian monozygotic twins. Neurology 53 : 1332-1335, 1999
DOI
|
70 |
Aoyagi M, Fukai N, Sakamoto H, Shinkai T, Matsushima Y, Yamamoto M, et al. : Altered cellular responses to serum mitogens, including platelet-derived growth factor, in cultured smooth muscle cells derived from arteries of patients with moyamoya disease. J Cell Physiol 147 : 191-198, 1991
DOI
|
71 |
Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, et al. : Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21 : 7724-7232, 2001
DOI
|
72 |
Baba T, Houkin K, Kuroda S : Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry 79 : 900-904, 2008
DOI
|
73 |
Bonduel M, Hepner M, Sciuccati G, Torres AF, Tenembaum S : Prothrombotic disorders in children with moyamoya syndrome. Stroke 32 : 1786-1792, 2001
DOI
|
74 |
Burke GM, Burke AM, Sherma AK, Hurley MC, Batjer HH, Bendok BR : Moyamoya disease : a summary. Neurosurg Focus 26 : E11, 2009
|
75 |
Cao Y, Hong A, Schulten H, Post MJ : Update on therapeutic neovascularization. Cardiovasc Res 65 : 639-648, 2005
DOI
|
76 |
Cho HJ, Jung YH, Kim YD, Nam HS, Kim DS, Heo JH : The different infarct patterns between adulthood-onset and childhood-onset moyamoya disease. J Neurol Neurosurg Psychiatry 82 : 38-40, 2011
DOI
|
77 |
Fujimura M, Watanabe M, Narisawa A, Shimizu H, Tominaga T : Increased expression of serum Matrix Metalloproteinase-9 in patients with moyamoya disease. Surg Neurol 72 : 476-480; discussion 480, 2009
DOI
|
78 |
Fukui M : Current state of study on moyamoya disease in Japan. Surg Neurol 47 : 138-143, 1997
DOI
|